One year in review 2017: Primary Sjögren's syndrome

Clinical and Experimental Rheumatology

Volumn 35, Issue 2, 2017, Pages 179-191

  Ferro, Francesco ^a   Marcucci, Elisa ^b   Orlandi, Martina ^c   Baldini, Chiara ^a   Bartoloni Bocci, Elena ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Biomarkers; Pathogenesis; Sj gren's syndrome; Treatment

Indexed keywords

B CELL ACTIVATING FACTOR RECEPTOR; BELIMUMAB; CD20 ANTIGEN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; COMPLEMENT COMPONENT C3D RECEPTOR; CRYOGLOBULIN; CXCL13 CHEMOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN A; INFLIXIMAB; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 2; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 16; INTERLEUKIN 18; INTERLEUKIN 36; LYMPHOTOXIN; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; PATHOGEN ASSOCIATED MOLECULAR PATTERN; RITUXIMAB; SECONDARY LYMPHOID TISSUE CHEMOKINE; TOCILIZUMAB; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; UNINDEXED DRUG; IMMUNOLOGIC FACTOR;

ADAPTIVE IMMUNITY; CRYOGLOBULINEMIA; DEPRESSION; DNA METHYLATION; EPIGENETICS; FATIGUE; GENE EXPRESSION; HUMAN; HYPERGAMMAGLOBULINEMIA; INFLAMMATION; INNATE IMMUNITY; LYMPHOCYTIC INFILTRATION; META ANALYSIS (TOPIC); MOLECULAR GENETICS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; PROTEIN EXPRESSION; PUBLICATION; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SALIVARY GLAND FUNCTION; SHORT FORM 36; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; SYSTEMATIC REVIEW (TOPIC); TH17 CELL; ANIMAL; CLINICAL TRIAL (TOPIC); COMORBIDITY; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; METHODOLOGY; PREDICTIVE VALUE; PROCEDURES; SJOGREN'S SYNDROME;

ADAPTIVE IMMUNITY; ANIMALS; CLINICAL TRIALS AS TOPIC; COMORBIDITY; EPIGENESIS, GENETIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; PREDICTIVE VALUE OF TESTS; RESEARCH DESIGN; RISK FACTORS; SJOGREN'S SYNDROME;

EID: 85018180440     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. BALDINI C, PEPE P, QUARTUCCIO L et al.: Primary Sjögren's syndrome as a multiorgan disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology (Oxford) 2014; 53: 839-44.
2. BRITO-ZERON P, BALDINI C, BOOTSMA H et al.: Sjögren syndrome. Nat Rev Dis Primers 2016; 2: 16047.
3. GOULES AV, TZIOUFAS AG: Primary Sjögren's syndrome: Clinical phenotypes, outcome and the development of biomarkers. Autoimmun Rev 2016; 15: 695-703.
4. BARONE F, COLAFRANCESCO S: Sjögren's syndrome: from pathogenesis to novel therapeutic targets. Clin Exp Rheumatol 2016; 34 (Suppl. 98): S58-62.
5. BRITO-ZERON P, ACAR-DENIZLI N, ZEHER M et al.: Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium. Ann Rheum Dis 2016 Nov 29. [Epub ahead of print].
6. LUCIANO N, VALENTINI V, CALABRO A et al.: One year in review 2015: Sjögren's syndrome. Clin Exp Rheumatol 2015; 33: 259-71.
7. FERRO F, VAGELLI R, BRUNI C et al.: One year in review 2016: Sjögren's syndrome. Clin Exp Rheumatol 2016; 34: 161-71.
8. LIU K, KURIEN BT, ZIMMERMAN SL et al.: X chromosome dose and sex bias in autoimmune diseases: increased prevalence of 47, XXX in systemic lupus erythematosus and Sjögren's syndrome. Arthritis Rheumatol 2016; 68: 1290-300.
9. VLACHOGIANNIS NI, NEZOS A, TZIOUFAS AG, KOUTSILIERIS M, MOUTSOPOULOS HM, MAVRAGANI CP: Increased frequency of the PTPN22W variant in primary Sjögren's syndrome: association with low type I IFN scores. Clin Immunol 2016; 173: 157-60.
10. JOHNSEN SJ, GUDLAUGSSON E, SKALAND I et al.: Low protein A20 in minor salivary glands is associated with lymphoma in primary Sjögren's syndrome. Scand J Immunol 2016; 83: 181-7.
11. NOCTURNE G, BOUDAOUD S, MICELIRICHARD C et al.: Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjögren's syndrome. Blood 2013;122: 4068-76.
12. NOCTURNE G, TARN J, BOUDAOUD S et al.: Germline variation of TNFAIP3 in primary Sjögren's syndrome-associated lymphoma. Ann Rheum Dis 2016; 75: 780-3.
13. SISTO M, BARCA A, LOFRUMENTO DD, LISI S: Downstream activation of NF-kappaB in the EDA-A1/EDAR signalling in Sjögren's syndrome and its regulation by the ubiquitin-editing enzyme A20. Clin Exp Immunol 2016; 184: 183-96.
14. GALLO A, BALDINI C, TEOS L, MOSCA M, BOMBARDIERI S, ALEVIZOS I: Emerging trends in Sjögren's syndrome: basic and translational research. Clin Exp Rheumatol 2012; 30: 779-84.
15. WILLIAMS AE, CHOI K, CHAN AL et al.: Sjögren's syndrome-associated microRNAs in CD14(+) monocytes unveils targeted TGFbeta signaling. Arthritis Res Ther 2016; 18: 95.
16. KONSTA OD, LE DANTEC C, CHARRAS A et al.: Defective DNA methylation in salivary gland epithelial acini from patients with Sjögren's syndrome is associated with SSB gene expression, anti-SSB/LA detection, and lymphocyte infiltration. J Autoimmun 2016; 68: 30-8.
17. COLE MB, QUACH H, QUACH D et al.: Epigenetic Signatures of salivary gland in flammation in Sjögren's syndrome. Arthritis Rheumatol 2016; 68: 2936-44.
18. MICELI-RICHARD C, WANG-RENAULT SF, BOUDAOUD S et al.: Overlap between differentially methylated DNA regions in blood B lymphocytes and genetic at-risk loci in primary Sjögren's syndrome. Ann Rheum Dis 2016; 75: 933-40.
19. IMGENBERG-KREUZ J, SANDLING JK, ALMLOF JC et al.: Genome-wide DNA methylation analysis in multiple tissues in primary Sjögren's syndrome reveals regulatory effects at interferon-induced genes. Ann Rheum Dis 2016; 75: 2029-36.
20. BRAEKKE NORHEIM K, IMGENBERGKREUZ J, JONSDOTTIR K et al.: Epigenomewide DNA methylation patterns associated with fatigue in primary Sjögren's syndrome. Rheumatology (Oxford) 2016; 55: 1074-82.
21. WANG J, PENG H, TIAN J et al.: Upregulation of long noncoding RNA TMEVPG1 enhances T helper type 1 cell response in patients with Sjögren syndrome. Immunol Res 2016; 64: 489-96.
22. SHI H, CAO N, PU Y, XIE L, ZHENG L, YU C: Long non-coding RNA expression profile in minor salivary gland of primary Sjögren's syndrome. Arthritis Res Ther 2016; 18: 109.
23. NARKEVICIUTE I, SUDZIUS G, MIELIAUSKAITE D et al.: Are cytotoxic effector cells changes in peripheral blood of patients with Sjögren's syndrome related to persistent virus infection: Suggestions and conundrums. Cell Immunol 2016; 310: 123-30.
24. MAVRAGANI CP, SAGALOVSKIY I, GUO Q et al.: Expression of long interspersed nuclear element 1 retroelements and induction of type I interferon in patients with systemic autoimmune disease. Arthritis Rheumatol 2016; 68: 2686-96.
25. MARIA NI, VAN HELDEN-MEEUWSEN CG, BRKIC Z et al.: Association of increased treg cell levels with elevated indoleamine 2, 3-dioxygenase activity and an imbalanced kynurenine pathway in interferon-positive primary Sjögren's syndrome. Arthritis Rheumatol 2016; 68: 1688-99.
26. KARLSEN M, JAKOBSEN K, JONSSON R, HAMMENFORS D, HANSEN T, APPEL S: Expression of Toll-like receptors in peripheral blood mononuclear cells of patients with primary Sjögren's syndrome. Scand J Immunol 2016 Dec 10. [Epub ahead of print].
27. MARIA NI, STEENWIJK EC, AS IJ et al.: Contrasting expression pattern of RNAsensing receptors TLR7, RIG-I and MDA5 in interferon-positive and interferon-negative patients with primary Sjögren's syndrome. Ann Rheum Dis 2016 Sep 26. [Epub ahead of print].
28. SISTO M, LORUSSO L, LISI S: Interleukin-15 as a potential new target in Sjögren's syndrome-associated inflammation. Pathology 2016; 48: 602-7.
29. SISTO M, LORUSSO L, LISI S: TLR2 signals via NF-kappaB to drive IL-15 production in salivary gland epithelial cells derived from patients with primary Sjögren's syndrome. Clin Exp Med 2016 Jun 3. [Epub ahead of print].
30. NICAISE C, WEICHSELBAUM L, SCHANDENE L et al.: Phagocyte-specific S100A8/ A9 is upregulated in primary Sjögren's syndrome and triggers the secretion of proinflammatory cytokines in vitro. Clin Exp Rheumatol 2017; 35: 129-36.
31. BALARINI GM, ZANDONADE E, TANURE L et al.: Serum calprotectin is a biomarker of carotid atherosclerosis in patients with primary Sjögren's syndrome. Clin Exp Rheumatol 2016; 34: 1006-12.
32. GIUSTI L, BALDINI C, BAZZICHI L, BOMBARDIERI S, LUCACCHINI A: Proteomic diagnosis of Sjögren's syndrome. Expert Rev Proteomics 2007; 4: 757-67.
33. BALDINI C, GIUSTI L, CIREGIA F et al.: Proteomic analysis of saliva: a unique tool to distinguish primary Sjögren's syndrome from secondary Sjögren's syndrome and other sicca syndromes. Arthritis Res Ther 2011; 13: R194.
34. LAVOIE TN, CARCAMO WC, WANCHOO A et al.: IL-22 regulation of functional gene expression in salivary gland cells. Genom Data 2016; 7: 178-84.
35. GUGGINO G, CICCIA F, RAIMONDO S et al.: Invariant NKT cells are expanded in peripheral blood but are undetectable in salivary glands of patients with primary Sjögren's syndrome. Clin Exp Rheumatol 2016; 34: 25-31.
36. WANG JJ, MACARDLE C, WEEDON H, BEROUKAS D, BANOVIC T: Mucosal-associated invariant T cells are reduced and functionally immature in the peripheral blood of primary Sjögren's syndrome patients. Eur J Immunol 2016; 46: 2444-53.
37. NIU L, ZHANG S, WU J, CHEN L, WANG Y: Upregulation of NLRP3 inflammasome in the tears and ocular surface of dry eye patients. PLoS One 2015; 10: e0126277.
38. THEOHARIDES TC, PETRA AI, TARACANOVA A, PANAGIOTIDOU S, CONTI P: Targeting IL-33 in autoimmunity and inflammation. J Pharmacol Exp Ther 2015; 354: 24-31.
39. MARGIOTTA DP, NAVARINI L, VADACCA M et al.: The IL33/ST2 axis in Sjögren syndrome in relation to disease activity. Eur Rev Med Pharmacol Sci 2016; 20: 1295-9.
40. BALDINI C, ROSSI C, FERRO F et al.: The P2X7 receptor-inflammasome complex has a role in modulating the inflammatory response in primary Sjögren's syndrome. J Intern Med 2013; 274: 480-9.
41. CICCIA F, ACCARDO-PALUMBO A, ALESSANDRO R et al.: Interleukin-36alpha axis is modulated in patients with primary Sjögren's syndrome. Clin Exp Immunol 2015; 181: 230-8.
42. BENCHABANE S, BOUDJELIDA A, TOUMI R, BELGUENDOUZ H, YOUINOU P, TOUILBOUKOFFA C: A case for IL-6, IL-17A, and nitric oxide in the pathophysiology of Sjögren's syndrome. Int J Immunopathol Pharmacol 2016; 29: 386-97.
43. TZIOUFAS AG, VLACHOYIANNOPOULOS PG: Sjögren's syndrome: an update on clinical, basic and diagnostic therapeutic aspects. J Autoimmun 2012; 39: 1-3.
44. CHRISTODOULOU MI, KAPSOGEORGOU EK, MOUTSOPOULOS HM: Characteristics of the minor salivary gland infiltrates in Sjögren's syndrome. J Autoimmun 2010; 34: 400-7.
45. DING J, ZHANG W, HASKETT S et al.: BAFF overexpression increases lymphocytic infiltration in Sjögren's target tissue, but only inefficiently promotes ectopic B-cell differentiation. Clin Immunol 2016; 169: 69-79.
46. ALUNNO A, IBBA-MANNESCHI L, BISTONI O et al.: Mobilization of lymphatic endothelial precursor cells and lymphatic neovascularization in primary Sjögren's syndrome. J Cell Mol Med 2016; 20: 613-22.
47. ZHAO L, NOCTURNE G, HASKETT S et al.: Clinical relevance of RORgamma positive and negative subsets of CD161+CD4+ T cells in primary Sjögren's syndrome. Rheumatology (Oxford) 2017; 56: 303-12.
48. LEE KE, KANG JH, YIM YR et al.: Predictive significance of CCL21 and CXCL13 levels in the minor salivary glands of patients with Sjögren's syndrome. Clin Exp Rheumatol 2016 Oct 21. [Epub ahead of print].
49. CORSIERO E, NERVIANI A, BOMBARDIERI M, PITZALIS C: Ectopic lymphoid structures: powerhouse of autoimmunity. Front Immunol 2016; 7: 430.
50. SZABO K, PAPP G, SZANTO A, TARR T, ZEHER M: A comprehensive investigation on the distribution of circulating follicular T helper cells and B cell subsets in primary Sjögren's syndrome and systemic lupus erythematosus. Clin Exp Immunol 2016; 183: 76-89.
51. HILLEN MR, BLOKLAND SL, RISSELADA AP et al.: High soluble IL-7 receptor expression in Sjögren's syndrome identifies patients with increased immunopathology and dryness. Ann Rheum Dis 2016; 75: 1735-6.
52. BRITO-ZERON P, THEANDER E, BALDINI C et al.: Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations. Expert Rev Clin Immunol 2016; 12: 137-56.
53. NOCTURNE G, VIRONE A, NG WF et al.: Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjögren's syndrome. Arthritis Rheumatol 2016; 68: 977-85.
54. FRAGKIOUDAKI S, MAVRAGANI CP, MOUTSOPOULOS HM: Predicting the risk for lymphoma development in Sjögren syndrome: An easy tool for clinical use. Medicine (Baltimore) 2016; 95: e3766.
55. BALDINI C, PEPE P, LUCIANO N et al.: A clinical prediction rule for lymphoma development in primary Sjögren's syndrome. J Rheumatol 2012; 39: 804-8.
56. TOMI AL, BELKHIR R, NOCTURNE G et al.: Brief report: monoclonal gammopathy and risk of lymphoma and multiple myeloma in patients with primary Sjögren's syndrome. Arthritis Rheumatol 2016; 68: 1245-50.
57. RETAMOZO S, GHEITASI H, QUARTUCCIO L et al.: Cryoglobulinaemic vasculitis at diagnosis predicts mortality in primary Sjögren syndrome: analysis of 515 patients. Rheumatology (Oxford) 2016; 55: 1443-51.
58. CARVAJAL ALEGRIA G, GUELLEC D, MARIETTE X et al.: Epidemiology of neurological manifestations in Sjögren's syndrome: data from the French ASSESS Cohort. RMD Open 2016; 2: e000179.
59. TAY SH, FAIRHURST AM, MAK A: Clinical utility of circulating anti-N-methyl-D aspartate receptor subunits NR2A/B antibody for the diagnosis of neuropsychiatric syndromes in systemic lupus erythematosus and Sjögren's syndrome: an updated metaanalysis. Autoimmun Rev 2017; 16: 114-22.
60. JASIEK M, KARRAS A, LE GUERN V et al.: A multicentre study of 95 biopsy-proven cases of renal disease in primary Sjögren's syndrome. Rheumatology (Oxford). 2016.
61. SHIBOSKI CH, SHIBOSKI SC, SEROR R et al.: 2016 American College of Rheumatology/ European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol 2017; 69: 35-45.
62. BALDINI C, TALARICO R, TZIOUFAS AG, BOMBARDIERI S: Classification criteria for Sjögren's syndrome: a critical review. J Autoimmun 2012; 39: 9-14.
63. JOUSSE-JOULIN S, MILIC V, JONSSON MV et al.: Is salivary gland ultrasonography a useful tool in Sjögren's syndrome? A systematic review. Rheumatology (Oxford) 2016; 55: 789-800.
64. VITALI C, BOMBARDIERI S, JONSSON R et al.: Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-8.
65. FISHER BA, JONSSON R, DANIELS T et al.: Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndrome. Ann Rheum Dis 2016 Dec 13. [Epub ahead of print].
66. SEROR R, BOOTSMA H, SARAUX A et al.: Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis 2016; 75: 382-9.
67. BRITO-ZERON P, KOSTOV B, SOLANS R et al.: Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients. Ann Rheum Dis 2016; 75: 348-55.
68. SEROR R, MEINERS P, BARON G et al.: Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies. Ann Rheum Dis 2016; 75: 1945-50.
69. CORNEC D, DEVAUCHELLE-PENSEC V, MARIETTE X et al.: Severe health-related quality-of-life impairment in active primary sSjögren's syndrome is driven by patientreported outcomes: data from a large therapeutic trial. Arthritis Care Res (Hoboken) 2016 Jul 7. [Epub ahead of print].
70. KARAGEORGAS T, FRAGIOUDAKI S, NEZOS A, KARAISKOS D, MOUTSOPOULOS HM, MAVRAGANI CP: Fatigue in primary Sjögren's syndrome: clinical, laboratory, psychometric, and biologic associations. Arthritis Care Res (Hoboken) 2016; 68: 123-31.
71. HOWARD TRIPP N, TARN J, NATASARI A et al.: Fatigue in primary Sjögren's syndrome is associated with lower levels of proinflammatory cytokines. RMD Open 2016; 2: e000282.
72. PERTOVAARA M, KORPELA M: Regular physical activity is associated with lower levels of ESSPRI and other favourable patient-reported outcomes in patients with primary Sjögren's syndrome. Clin Exp Rheumatol 2016; 34: 560.
73. NG WF, MILLER A, BOWMAN SJ et al.: Physical activity but not sedentary activity is reduced in primary Sjögren's syndrome. Rheumatol Int 2016 Dec 24. [Epub ahead of print].
74. RUA-FIGUEROA I, FERNANDEZ CASTRO M, ANDREU JL et al.: Comorbidities in patients with primary Sjögren's syndrome and systemic lupus erythematosus: a comparative registries-based study. Arthritis Care Res (Hoboken) 2017; 69:38-45.
75. BIRT JA, TAN Y, MOZAFFARIAN N: Sjögren's syndrome: managed care data from a large United States population highlight realworld health care burden and lack of treatment options. Clin Exp Rheumatol 2017; 35: 98-107.
76. BALARINI GM, ZANDONADE E, TANURE L et al.: Serum calprotectin is a biomarker of carotid atherosclerosis in patients with primary Sjögren's syndrome. Clin Exp Rheumatol 2016; 34: 1006-12.
77. CHOI BY, OH HJ, LEE YJ, SONG YW: Prevalence and clinical impact of fibromyalgia in patients with primary Sjögren's syndrome. Clin Exp Rheumatol 2016; 34 (Suppl. 96): S9-13.
78. HACKETT KL, GOTTS ZM, ELLIS J et al.: An investigation into the prevalence of sleep disturbances in primary Sjögren's syndrome: a systematic review of the literature. Rheumatology (Oxford) 2016 Dec 24. [Epub ahead of print].
79. PRIORI R, MINNITI A, ANTONAZZO B, FUSCONI M, VALESINI G, CURCIO G: Sleep quality in patients with primary Sjögren's syndrome. Clin Exp Rheumatol 2016; 34: 373-9.
80. BAER AN, MEDRANO L, McADAMS-DEMARCO M, GNIADEK TJ: Association of anticentromere antibodies with more severe exocrine glandular dysfunction in Sjögren's syndrome: analysis of the Sjögren's International Collaborative Clinical Alliance Cohort. Arthritis Care Res (Hoboken) 2016; 68: 1554-9.
81. BALDINI C, MOSCA M, Della ROSSA A et al.: Overlap of ACA-positive systemic sclerosis and Sjögren's syndrome: a distinct clinical entity with mild organ involvement but at high risk of lymphoma. Clin Exp Rheumatol 2013; 31: 272-80.
82. BOURNIA VK, DIAMANTI KD, VLACHOYIANNOPOULOS PG, MOUTSOPOULOS HM: Anticentromere antibody positive Sjögren's Syndrome: a retrospective descriptive analysis. Arthritis Res Ther 2010; 12: R47.
83. BAER AN, PETRI M, SOHN J, ROSEN A, CASCIOLA-ROSEN L: Antibodies to interferoninducible protein-16 in primary Sjögren's syndrome are associated with markers of more severe diseas. Arthritis Care Res (Hoboken) 2016 May 9. [Epub ahead of print].
84. DELALEU N, MYDEL P, BRUN JG, JONSSON MV, ALIMONTI A, JONSSON R: Sjögren's syndrome patients with ectopic germinal centers present with a distinct salivary proteome. Rheumatology (Oxford) 2016; 55: 1127-37.
85. MINGUENEAU M, BOUDAOUD S, HASKETT S et al.: Cytometry by time-of-flight immunophenotyping identifies a blood Sjögren's signature correlating with disease activity and glandular inflammation. J Allergy Clin Immunol 2016; 137: 1809-21 e12.
86. CARSONS SE, VIVINO FB, PARKE A et al.: Treatment Guidelines for Rheumatologic Manifestations of Sjögren's: use of biologics, management of fatigue and inflammatory musculoskeletal pain. Arthritis Care Res (Hoboken) 2016 Jul 7. [Epub ahead of print].
87. SAMBATARO D, SAMBATARO G, Dal BOSCO Y, POLOSA R: Present and future of biologic drugs in primary Sjögren's syndrome. Expert Opin Biol Ther 2017; 17: 63-75.
88. DEVAUCHELLE-PENSEC V, MARIETTE X, JOUSSE-JOULIN S et al.: Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med 2014; 160: 233-42.
89. CORNEC D, DEVAUCHELLE-PENSEC V, MARIETTE X et al.: Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy. Rheumatology (Oxford) 2015; 54: 1699-708.
90. CORNEC D, COSTA S, DEVAUCHELLEPENSEC V et al.: Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome. J Autoimmun 2016; 67: 102-10.
91. CORNEC D, JOUSSE-JOULIN S, COSTA S et al.: High-grade salivary-gland involvement, assessed by histology or ultrasonography, is associated with a poor response to a single rituximab course in primary Sjögren's syndrome: data from the TEARS randomized trial. PLoS One 2016; 11: e0162787.
92. DELLI K, HAACKE EA, KROESE FG et al.: In primary Sjögren's syndrome high absolute numbers and proportions of B cells in parotid glands predict responsiveness to rituximab as defined by ESSDAI, but not by SSRI. Ann Rheum Dis 2016;75: e34.
93. CHEN MH, CHEN CK, CHOU HP, CHEN MH, TSAI CY, CHANG DM: Rituximab therapy in primary Sjögren's syndrome with interstitial lung disease: a retrospective cohort study. Clin Exp Rheumatol 2016; 34: 1077-84.
94. SOUZA FB, PORFIRIO GJ, ANDRIOLO BN, ALBUQUERQUE JV, TREVISANI VF: Rituximab effectiveness and safety for treating primary Sjögren's syndrome (pSS): Systematic review and meta-Analysis. PLoS One 2016; 11: e0150749.
95. MARIETTE X, SEROR R, QUARTUCCIO L et al.: Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis 2015; 74: 526-31.
96. QUARTUCCIO L, SALVIN S, CORAZZA L, GANDOLFO S, FABRIS M, DE VITA S: Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjögren's syndrome: follow-up after the end of the phase II open-label BELISS study. Clin Exp Rheumatol 2016; 34: 311-4.
97. ADLER S, KORNER M, FORGER F, HUSCHER D, CAVERSACCIO MD, VILLIGER PM: Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sjögren's syndrome: a pilot study. Arthritis Care Res (Hoboken) 2013; 65: 1862-8.
98. MEINERS PM, VISSINK A, KROESE FG et al.: Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study). Ann Rheum Dis 2014; 73: 1393-6.
99. HAACKE EA, VAN DER VEGT B, MEINERS PM et al.: Abatacept treatment of patients with primary Sjögren's syndrome results in a decrease of germinal centres in salivary gland tissue. Clin Exp Rheumatol 2016 Nov 12 [Epub ahead of print].
100. TSUBOI H, MATSUMOTO I, HAGIWARA S et al.: Effectiveness of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjögren's syndrome Endocrinopathy) trial. Mod Rheumatol 2016: 1-9.
101. HASKETT S, DING J, ZHANG W et al.: Identification of novel CD4+ T cell subsets in the target tissue of Sjögren's syndrome and their differential regulation by the lymphotoxin/ LIGHT signaling axis. J Immunol 2016; 197: 3806-19.
102. TAHARA M, TSUBOI H, SEGAWA S et al.: RORγt antagonist suppresses M3 muscarinic acetylcholine receptor-induced Sjögren's syndrome-like sialadenitis. Clin Exp Immunol 2017; 187: 213-24.
103. IIZUKA M, TSUBOI H, MATSUO N et al.: A crucial role of RORgt in the development of spontaneous sialadenitis-like Sjögren's syndrome. J Immunol 2015; 194: 56-67.